Skip to main content
Premium Trial:

Request an Annual Quote

Holden to Leave Illumina; Yousaf Tapped to Head ABI’s MCB Systems Group; NIGMS Appoints Lee as Executive Officer, and Others

NEW YORK (GenomeWeb News) - Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said this week in a filing with the US Securities and Exchange Commission.
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced this week that aims to find genetic causes for severe adverse events that hamper drug development.
Holden formerly was chairman and CEO of First Genetic Trust. He also served aschairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium, and as CEO of the SNP Consortium.

Shaf Yousaf has joined Applied Biosystems as president of the Molecular and Cell Biology Systems division. He joined ABI from Sigma-Aldrich, where he was president of the research biotech business unit.
In July, Applied Biosystems split its Molecular and Cell Division into two groups: MCB Systems and MCB Consumables.
At the time, Mark Stevenson, president of the Molecular and Cell Division, was promoted to executive vice president of the company. Peter Dansky heads the MCB Consumables group.

The National Institute of General Medical Sciences has appointed Sally Lee to be executive officer. Lee will manage finances, administrative functions, information technology, and management analysis. Lee has been at NIGMS since 1988 and has been a management analyst since 1991.

Med BioGene has named Melanie Mahtani to be executive advisor of commercial development. Mahtani formerly was director of microarray systems at Amersham Biosciences, vice president of corporate business development at Panomics, and a fellow at the Whitehead Institute for Biomedical Research.

Sigma-Aldrich has named Patrick Sullivan as vice president of R&D for its Research Biotech business unit. Sullivan has nearly 20 years of experience in genomics and pharmaceutical businesses, including Monsanto/Searle/Pharmacia, Incyte Genomics and Pfizer.
Sullivan has been on Sigma-Aldrich’s scientific advisory board since 2005.

Exagen Diagnostics said this week it has hired Barbara Preisel-Simmons to be senior director of clinical affairs, a new position focused on overseeing clinical trials. Preisel-Simmons previously worked for Siemens Medical Solutions Diagnostics, Bayer HealthCare, Chiron Diagnostics, Abbott Laboratories and Baxter Healthcare.

Simulations Plus said this week that it has hired John Crison as director of life sciences. He takes the reins from Michael Bolger, who will continue with the company in the role of chief scientist.
Crison formerly was an associate research fellow at Pfizer and for two years was VP of pharmaceutical products at MediVas.

The United Hospital Fund at an annual gala this week honored Charles Bronfman with the Distinguished Community Service Award for his gift of $12.5 million. Bronfman provided the funding to establish the Charles R. Bronfman Institute for Personalized Medicine at the Mount Sinai Medical Center.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.